Amanda L. McCormick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda L. McCormick has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Trevor S. Anderson
Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas
14 shared publications - Caryn Lawrence
Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas
13 shared publications - Devin B. Lowe
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
13 shared publications - Duke Appiah
Julia Jones Matthews School of Population and Public Health, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
13 shared publications - Elizabeth A. Daugherity
Department of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA
13 shared publications - Izuchukwu F. Okpalanwaka
Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas
13 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Table 1 annotates sequences for the bsAb VH/VL.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Table 1 annotates sequences for the bsAb VH/VL.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Colorectal cancer is a leading cause of cancer-related deaths worldwide. The current standard of care for patients may involve surgery, chemotherapy, and immune checkpoint inhibitors, but these approaches typically fail to secure durable responses against late-stage disease. Regorafenib (REG) is an FDA-approved tyrosine kinase inhibitor with immunomodulating properties for patients with colorectal cancer who progress on standard care, but 5-year relative survival rates for individuals dosed with the drug as a monotherapy are poor. We hypothesize that REG may be more appropriately leveraged alongside immunotherapeutic agents that specifically stimulate T-cell infiltration and activation within the tumor microenvironment (TME). We engineered a PD-L1/CD3 bispecific antibody (bsAb) that simultaneously binds PD-L1–expressing colorectal cancer cells and stimulates activated T cells in order to investigate combination strategies with REG in preclinical models of colorectal cancer. Combined REG + bsAb therapy safely initiated and sustained inhibition against MC38 and CT26 progression in vivo, and these effects correlated to improved CD8+ T-cell infiltration and activity within a type 1–prone TME. Additionally, cytotoxic CD8+ T cells from REG + bsAb–sensitized mice exhibited heightened tumor cell reactivity compared with animals treated with either agent alone. Therefore, the immunomodulatory benefits of REG can be effectively paired with a bsAb that anchors to colorectal cancer cells, diminishes immunosuppression (through PD-L1 blockade), and activates/sustains antigen-specific CD8+ T cells within the TME. Our newly described REG + bsAb regimen led to improved antitumor outcomes preclinically and may represent a promising future approach for patients with colorectal cancer.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Colorectal cancer is a leading cause of cancer-related deaths worldwide. The current standard of care for patients may involve surgery, chemotherapy, and immune checkpoint inhibitors, but these approaches typically fail to secure durable responses against late-stage disease. Regorafenib (REG) is an FDA-approved tyrosine kinase inhibitor with immunomodulating properties for patients with colorectal cancer who progress on standard care, but 5-year relative survival rates for individuals dosed with the drug as a monotherapy are poor. We hypothesize that REG may be more appropriately leveraged alongside immunotherapeutic agents that specifically stimulate T-cell infiltration and activation within the tumor microenvironment (TME). We engineered a PD-L1/CD3 bispecific antibody (bsAb) that simultaneously binds PD-L1–expressing colorectal cancer cells and stimulates activated T cells in order to investigate combination strategies with REG in preclinical models of colorectal cancer. Combined REG + bsAb therapy safely initiated and sustained inhibition against MC38 and CT26 progression in vivo, and these effects correlated to improved CD8+ T-cell infiltration and activity within a type 1–prone TME. Additionally, cytotoxic CD8+ T cells from REG + bsAb–sensitized mice exhibited heightened tumor cell reactivity compared with animals treated with either agent alone. Therefore, the immunomodulatory benefits of REG can be effectively paired with a bsAb that anchors to colorectal cancer cells, diminishes immunosuppression (through PD-L1 blockade), and activates/sustains antigen-specific CD8+ T cells within the TME. Our newly described REG + bsAb regimen led to improved antitumor outcomes preclinically and may represent a promising future approach for patients with colorectal cancer.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 1 shows ICD induction in CT26 following REG exposure.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 1 shows ICD induction in CT26 following REG exposure.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 3 indicates bsAb binding PD-L1 on tumor cells after exposure to REG.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 3 indicates bsAb binding PD-L1 on tumor cells after exposure to REG.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 5 details improved CD8+ T cell infiltration and apoptosis in the CT26 TME after REG/bsAb treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 5 details improved CD8+ T cell infiltration and apoptosis in the CT26 TME after REG/bsAb treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 7 demonstrates enhanced CD8+ T cell exhaustion after REG/bsAb therapy.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 7 demonstrates enhanced CD8+ T cell exhaustion after REG/bsAb therapy.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 9 confirms abscopal tumor effects after local REG/bsAb treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 9 confirms abscopal tumor effects after local REG/bsAb treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Table 2 lists qPCR primers used.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Table 2 lists qPCR primers used.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 6 indicates improved Type-1-mediated immunity in the CT26 TME post REG/bsAb treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 6 indicates improved Type-1-mediated immunity in the CT26 TME post REG/bsAb treatment.